BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ijaz S, Bolea B, Davies S, Savović J, Richards A, Sullivan S, Moran P. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews. BMC Psychiatry 2018;18:275. [PMID: 30176844 DOI: 10.1186/s12888-018-1848-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Morell R, Curtis J, Watkins A, Poole J, Fibbins H, Rossimel E, Gerrard M, White A, Teasdale S, Ward PB, Lappin J. Cardio-metabolic risk in individuals prescribed long-acting injectable antipsychotic medication. Psychiatry Research 2019;281:112606. [DOI: 10.1016/j.psychres.2019.112606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ishikawa S, Yamamura R, Hashimoto N, Okubo R, Sawagashira R, Ito YM, Sato N, Kusumi I. The type rather than the daily dose or number of antipsychotics affects the incidence of hyperglycemic progression. Prog Neuropsychopharmacol Biol Psychiatry 2022;113:110453. [PMID: 34637872 DOI: 10.1016/j.pnpbp.2021.110453] [Reference Citation Analysis]
3 Zhu JH, Li W, Huo XN, Jin HM, Zhang CH, Yun JD, Gao LG, Cheung T, Hall BJ, Yang B, Xiang YT. The Attitude towards Preventive Measures and Knowledge of COVID-19 Inpatients with Severe Mental Illness in Economically Underdeveloped Areas of China. Psychiatr Q 2021;92:683-91. [PMID: 32889688 DOI: 10.1007/s11126-020-09835-1] [Reference Citation Analysis]
4 Cha HY, Yang SJ, Kim SW. Higher Dietary Inflammation in Patients with Schizophrenia: A Case-Control Study in Korea. Nutrients 2021;13:2033. [PMID: 34199231 DOI: 10.3390/nu13062033] [Reference Citation Analysis]
5 Zhang Q, He H, Bai X, Jiang L, Chen W, Zeng X, Li Y, Teixeira AL, Dai J. Unveiling the Metabolic Profile of First-Episode Drug-Naïve Schizophrenia Patients: Baseline Characteristics of a Longitudinal Study Among Han Chinese. Front Psychiatry 2021;12:702720. [PMID: 34305687 DOI: 10.3389/fpsyt.2021.702720] [Reference Citation Analysis]
6 Müller HHO, Moeller S. Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments - A Series of Two Cases. Neuropsychiatr Dis Treat 2021;17:1089-93. [PMID: 33883898 DOI: 10.2147/NDT.S303817] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Guan F, Ni T, Zhu W, Williams LK, Cui LB, Li M, Tubbs J, Sham PC, Gui H. Integrative omics of schizophrenia: from genetic determinants to clinical classification and risk prediction. Mol Psychiatry 2021. [PMID: 34193973 DOI: 10.1038/s41380-021-01201-2] [Reference Citation Analysis]
8 Zhong X, Ao Q, Xing F. Serum Levels of HCY, MIF, and hs-CRP Correlate with Glycolipid Metabolism in Adults with Never-Medicated First-Episode Schizophrenia. Evid Based Complement Alternat Med 2021;2021:7394699. [PMID: 34812265 DOI: 10.1155/2021/7394699] [Reference Citation Analysis]
9 Kornetova EG, Kornetov AN, Mednova IA, Goncharova AA, Gerasimova VI, Pozhidaev IV, Boiko AS, Semke AV, Loonen AJM, Bokhan NA, Ivanova SA. Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals. Front Psychiatry 2021;12:661174. [PMID: 34276438 DOI: 10.3389/fpsyt.2021.661174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Chang SC, Goh KK, Lu ML. Metabolic disturbances associated with antipsychotic drug treatment in patients with schizophrenia: State-of-the-art and future perspectives. World J Psychiatr 2021; 11(10): 696-710 [PMID: 34733637 DOI: 10.5498/wjp.v11.i10.696] [Reference Citation Analysis]
11 Doménech-Matamoros P. Influence of the use of atypical antipsychotics in metabolic syndrome. Rev Esp Sanid Penit 2020;22:80-6. [PMID: 32697278 DOI: 10.18176/resp.00014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Paderina DZ, Boiko AS, Pozhidaev IV, Bocharova AV, Mednova IA, Fedorenko OY, Kornetova EG, Loonen AJM, Semke AV, Bokhan NA, Ivanova SA. Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia. J Pers Med 2021;11:181. [PMID: 33807811 DOI: 10.3390/jpm11030181] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Azorin J, Simon N. Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale. Expert Opinion on Drug Metabolism & Toxicology 2020;16:1175-86. [DOI: 10.1080/17425255.2020.1821646] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Godin O, Leboyer M, Belzeaux R, Bellivier F, Loftus J, Courtet P, Dubertret C, Gard S, Henry C, Llorca PM, Schwan R, Passerieux C, Polosan M, Samalin L, Olié E, Etain B; FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) Collaborators. Non-alcoholic fatty liver disease in a sample of individuals with bipolar disorders: results from the FACE-BD cohort. Acta Psychiatr Scand 2021;143:82-91. [PMID: 33011976 DOI: 10.1111/acps.13239] [Reference Citation Analysis]
15 Lin SK. Antipsychotic Polypharmacy: A Dirty Little Secret or a Fashion? Int J Neuropsychopharmacol 2020;23:125-31. [PMID: 31867671 DOI: 10.1093/ijnp/pyz068] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
16 Mazereel V, Detraux J, Vancampfort D, van Winkel R, De Hert M. Impact of Psychotropic Medication Effects on Obesity and the Metabolic Syndrome in People With Serious Mental Illness. Front Endocrinol (Lausanne) 2020;11:573479. [PMID: 33162935 DOI: 10.3389/fendo.2020.573479] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 . Progress in Schizophrenia Research and Treatment. Focus (Am Psychiatr Publ) 2020;18:440-2. [PMID: 33343257 DOI: 10.1176/appi.focus.18310] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Chieh AY, Bryant BM, Kim JW, Li L. Systematic review investigating the relationship between autism spectrum disorder and metabolic dysfunction. Research in Autism Spectrum Disorders 2021;86:101821. [DOI: 10.1016/j.rasd.2021.101821] [Reference Citation Analysis]
19 Bryll A, Skrzypek J, Krzyściak W, Szelągowska M, Śmierciak N, Kozicz T, Popiela T. Oxidative-Antioxidant Imbalance and Impaired Glucose Metabolism in Schizophrenia. Biomolecules 2020;10:E384. [PMID: 32121669 DOI: 10.3390/biom10030384] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
20 Cao H, Meng Y, Li X, Ma X, Deng W, Guo W, Li T. The metabolic effects of antipsychotics in the early stage of treatment in first-episode patients with schizophrenia: A real-world study in a naturalistic setting.J Psychiatr Res. 2020;129:265-271. [PMID: 32827810 DOI: 10.1016/j.jpsychires.2020.07.038] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
21 Akkouh IA, Hughes T, Steen VM, Glover JC, Andreassen OA, Djurovic S, Szabo A. Transcriptome analysis reveals disparate expression of inflammation-related miRNAs and their gene targets in iPSC-astrocytes from people with schizophrenia. Brain Behav Immun 2021;94:235-44. [PMID: 33571628 DOI: 10.1016/j.bbi.2021.01.037] [Reference Citation Analysis]
22 Liu JCW, Gorbovskaya I, Hahn MK, Müller DJ. The Gut Microbiome in Schizophrenia and the Potential Benefits of Prebiotic and Probiotic Treatment. Nutrients 2021;13:1152. [PMID: 33807241 DOI: 10.3390/nu13041152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
23 Tan XW, Lee ES, Toh MPHS, Lum AWM, Seah DEJ, Leong KP, Chan CYW, Fung DSS, Tor PC. Comparison of mental-physical comorbidity, risk of death and mortality among patients with mental disorders - A retrospective cohort study. J Psychiatr Res 2021;142:48-53. [PMID: 34320455 DOI: 10.1016/j.jpsychires.2021.07.039] [Reference Citation Analysis]
24 Chen E, Bazargan-Hejazi S, Ani C, Hindman D, Pan D, Ebrahim G, Shirazi A, Banta JE. Schizophrenia hospitalization in the US 2005-2014: Examination of trends in demographics, length of stay, and cost. Medicine (Baltimore) 2021;100:e25206. [PMID: 33847618 DOI: 10.1097/MD.0000000000025206] [Reference Citation Analysis]
25 Foster A, King J. Antipsychotic Polypharmacy. Focus (Am Psychiatr Publ) 2020;18:375-85. [PMID: 33343249 DOI: 10.1176/appi.focus.20190047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Frajerman A, Morin V, Chaumette B, Kebir O, Krebs MO. [Management of cardiovascular co-morbidities in young patients with early onset psychosis: State of the art and therapeutic perspectives]. Encephale 2020;46:390-8. [PMID: 32571543 DOI: 10.1016/j.encep.2020.03.007] [Reference Citation Analysis]
27 de Filippis R, Gaetano R, Schoretsanitis G, Verde G, Oliveti CA, Kane JM, Segura-Garcia C, De Fazio P. Clozapine Management in Schizophrenia Inpatients: A 5-Year Prospective Observational Study of Its Safety and Tolerability Profile. Neuropsychiatr Dis Treat 2021;17:2141-50. [PMID: 34234440 DOI: 10.2147/NDT.S312095] [Reference Citation Analysis]